Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 14.1% in February

Fate Therapeutics, Inc. (NASDAQ:FATE) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 9,563,527 shares, a decrease of 14.1% from the February 12th total of 11,128,203 shares. Based on an average daily volume of 1,749,529 shares, the short-interest ratio is presently 5.5 days. Currently, 8.7% of the shares of the stock are short sold. Currently, 8.7% of the shares of the stock are short sold. Based on an average daily volume of 1,749,529 shares, the short-interest ratio is presently 5.5 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Fate Therapeutics in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Fate Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.10.

Fate Therapeutics Trading Down 6.2%

Shares of FATE opened at $1.06 on Thursday. The stock’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.18. Fate Therapeutics has a 12 month low of $0.66 and a 12 month high of $1.94. The company has a market capitalization of $123.24 million, a PE ratio of -0.92 and a beta of 2.19.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.27). Fate Therapeutics had a negative net margin of 2,051.08% and a negative return on equity of 55.02%. The firm had revenue of $1.37 million during the quarter, compared to analyst estimates of $1.20 million. Equities research analysts predict that Fate Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Trading of Fate Therapeutics

A number of institutional investors have recently bought and sold shares of FATE. Corient Private Wealth LLC acquired a new position in shares of Fate Therapeutics in the 4th quarter valued at about $29,000. Bridgeway Capital Management LLC acquired a new stake in Fate Therapeutics during the second quarter worth approximately $28,000. Commonwealth Equity Services LLC acquired a new stake in Fate Therapeutics during the fourth quarter worth approximately $26,000. Monaco Asset Management SAM increased its holdings in Fate Therapeutics by 7.8% in the fourth quarter. Monaco Asset Management SAM now owns 830,000 shares of the biopharmaceutical company’s stock worth $816,000 after purchasing an additional 60,000 shares in the last quarter. Finally, Privium Fund Management B.V. increased its holdings in Fate Therapeutics by 10.8% in the fourth quarter. Privium Fund Management B.V. now owns 369,100 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 35,881 shares in the last quarter. Institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.